{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:18:27Z","timestamp":1769548707708,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010438","name":"Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu","doi-asserted-by":"publisher","award":["502-14-33064130-09629"],"award-info":[{"award-number":["502-14-33064130-09629"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s13318-019-00555-x","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T13:04:43Z","timestamp":1555419883000},"page":"653-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In Vitro Study of the Enzymatic and Nonenzymatic Conjugation of Treosulfan with Glutathione"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-0613","authenticated-orcid":false,"given":"Micha\u0142","family":"Roma\u0144ski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciszek K.","family":"G\u0142\u00f3wka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"555_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00432-016-2307-0","volume":"143","author":"J Sehouli","year":"2017","unstructured":"Sehouli J, Tom\u00e8 O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, Chekerov R, Muallem MZ, Lux MP, Trarbach T, Gitsch G. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). J Cancer Res Clin Oncol. 2017;143:541\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"key":"555_CR2","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1002\/jps.24662","volume":"104","author":"M Roma\u0144ski","year":"2015","unstructured":"Roma\u0144ski M, Urbaniak B, Kokot Z, G\u0142\u00f3wka FK. Activation of prodrug treosulfan at pH 7.4 and 37 \u00b0C accompanied by hydrolysis of its active epoxides: kinetic studies with clinical relevance. J Pharm Sci. 2015;104:4433\u201342.","journal-title":"J Pharm Sci"},{"key":"555_CR3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.xphs.2017.03.018","volume":"106","author":"M Roma\u0144ski","year":"2017","unstructured":"Roma\u0144ski M, Ratajczak W, G\u0142\u00f3wka FG. Kinetic and mechanistic study of the pH-dependent activation (epoxidation) of prodrug treosulfan including the reaction inhibition in a borate buffer. J Pharm Sci. 2017;106:1917\u201322.","journal-title":"J Pharm Sci"},{"key":"555_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/sj.bjc.6690043","volume":"79","author":"JA Hartley","year":"1999","unstructured":"Hartley JA, O\u2019Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer. 1999;79:264\u20136.","journal-title":"Br J Cancer"},{"key":"555_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","volume":"173","author":"ER Nemecek","year":"2011","unstructured":"Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;173:341\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"key":"555_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pbc.25764","volume":"63","author":"H Boztug","year":"2016","unstructured":"Boztug H, Sykora KW, Slatter M, Zecca M, Veys P, Lankester A, Cant A, Skinner R, Wachowiak J, Glogova E, P\u00f6tschger U, Peters C. European Society for Blood and Marrow Transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies. Pediatr Blood Cancer. 2016;63:139\u201348.","journal-title":"Pediatr Blood Cancer"},{"key":"555_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12185-017-2320-3","volume":"106","author":"M Remberger","year":"2017","unstructured":"Remberger M, T\u00f6rlen J, Serafi IE, Garming-Legert K, Bj\u00f6rklund A, Ljungman P, Sundin M, Hassan M, Mattsson J. Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. Int J Hematol. 2017;106:471\u20135.","journal-title":"Int J Hematol"},{"key":"555_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:523\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"key":"555_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/157488407779422249","volume":"2","author":"CE Nath","year":"2007","unstructured":"Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007;2:75\u201391.","journal-title":"Curr Clin Pharmacol"},{"key":"555_CR10","first-page":"3678","volume":"56","author":"JP Gibbs","year":"1996","unstructured":"Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996;56:3678\u201381.","journal-title":"Cancer Res"},{"key":"555_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","volume":"13","author":"AL Myers","year":"2017","unstructured":"Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol. 2017;13:901\u201323.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"555_CR12","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","volume":"22","author":"J Palmer","year":"2016","unstructured":"Palmer J, McCune JS, Perales M-A, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22:1915\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"key":"555_CR13","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40262-018-0647-4","volume":"57","author":"M Roma\u0144ski","year":"2018","unstructured":"Roma\u0144ski M, Wachowiak J, G\u0142\u00f3wka FK. Treosulfan pharmacokinetics and its variability in pediatric and adult patients undergoing conditioning prior to hematopoietic stem cell transplantation: current state of the art, in-depth analysis, and perspectives. Clin Pharmacokinet. 2018;57:1255\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"555_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14960","volume":"179","author":"MYEC van der Stoep","year":"2017","unstructured":"van der Stoep MYEC, Bertaina A, Ten Brink MH, Bredius RG, Smiers FJ, Wanders DCM, Moes DJAR, Locatelli F, Guchelaar HJ, Zwaveling J, Lankester AC. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017;179:772\u201380.","journal-title":"Br J Haematol"},{"key":"555_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s002800051023","volume":"45","author":"RA Hilger","year":"2000","unstructured":"Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S, Scheulen ME. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol. 2000;45:483\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"555_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1006\/taap.1996.0037","volume":"136","author":"PJ Boogaard","year":"1996","unstructured":"Boogaard PJ, Sumner SC, Bond JA. Glutathione conjugation of 1,2:3,4- diepoxybutane in human liver and rat and mouse liver and lung in vitro. Toxicol Appl Pharmacol. 1996;136:307\u201316.","journal-title":"Toxicol Appl Pharmacol"},{"key":"555_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2008.08.006","volume":"30","author":"HJ Forman","year":"2009","unstructured":"Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30:1\u201312.","journal-title":"Mol Aspects Med"},{"key":"555_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.bbmt.2012.11.007","volume":"19","author":"D Choudhary","year":"2013","unstructured":"Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, Setia R, Katewa S. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Biol Blood Marrow Transplant. 2013;19:492\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"555_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.bmt.1705553","volume":"39","author":"M Sauer","year":"2007","unstructured":"Sauer M, Zeidler C, Meissner B, Rehe K, Hanke A, Welte K, Lohse P, Sykora KW. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2007;39:143\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00277-011-1253-9","volume":"91","author":"JM Chemnitz","year":"2012","unstructured":"Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Ann Hematol. 2012;91:47\u201355.","journal-title":"Ann Hematol"},{"key":"555_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/bmt.2015.202","volume":"50","author":"N Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger N, Bornh\u00e4user M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer RG, Bethge W, Kobbe G, Ayuk F, G\u00f6kbuget N, H\u00f6lzer D, Zander A, Beelen D. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). Bone Marrow Transplant. 2015;50:1503\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"555_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","volume":"25","author":"M Hassan","year":"2000","unstructured":"Hassan M, Ljungman P, Ringd\u00e9n O, Hassan Z, Oberg G, Nilsson C, B\u00e9kassy A, Bielenstein M, Abdel-Rehim M, Geor\u00e9n S, Astner L. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25:915\u201324.","journal-title":"Bone Marrow Transplant"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-019-00555-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T09:50:02Z","timestamp":1589881802000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-019-00555-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s13318-019-00555-x","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"16 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by the Poznan University of Medical Sciences, grant No. 502-14-33064130-09629. The Ministry of Science and Higher Education (Poland)\u00a0sponsored the open access publication under Springer\u2019s Open Choice option.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Roma\u0144ski and F.K. G\u0142\u00f3wka declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}